Table 2 Dose escalation and dose-limiting toxicities (first cycle of therapy)

From: Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

Saracatinib dose, mg

Saracatinib with C+P q3w ( N =24)

Saracatinib with C q3w ( N =21)

Saracatinib with P q3w ( N =27)

Saracatinib with P q1w ( N =24)

125

5/7

6/7

3/3

3/3

175

6/11

8/14

• Grade 3 fatigue

• Grade 3 colitis ulcerativea

6/6

• Grade 5 neutropenic sepsis

10/13

225

5/6

• Grade 3 hyponatraemia

—

4/7

6/8

• Grade 3 neutropenia

• Grade 4 febrile neutropenia

250

—

—

6/8

• Grade 3 febrile neutropenia

—

300

—

—

0/3

—

  1. Abbreviations: C=carboplatin; P=paclitaxel. Number of evaluable patients/total patients per cohort; bullet points indicate dose-limiting toxicities. aExacerbation of pre-existing condition.
Back to article page